Web Analytics

3 Latest Announced Rounds

  • $7,000,000

    1 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,300,000

    7 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,800,000

    4 Investors

    Software Development
    Apr 12th, 2024
$1,933.10M Raised in 90 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Engine Biosciences

start up
Singapore - Singapore, Singapore
  • 01/11/2023
  • Series A
  • $27,000,000

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.

In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Related People

Jeffrey LuCo Founder

Jeffrey Lu Singapore - Singapore

Passionate about innovative technologies, entrepreneurship and company building.

Currently building Engine Biosciences, a global venture-backed drug discovery company focused on addressing complex diseases using our integrated computing/machine learning, experimental biology, and drug design platform in the hands of proven drug developers.

Also have had extensive experience in investment, directorship, and advisory roles in high growth and high impact companies on behalf of VC fund and investment organisations. As founding director of Enleofen from 2017 onwards, had the good fortune of working with a great small team to advance a novel target in fibrosis to preclinical stage product candidates and a >US$1B per product acquisition by Boehringer Ingelheim, especially notable for its scale for a Singapore biotech.

Approx 15 years experience spanning investing, start-ups, and serving as a senior corporate executive in billion-dollar companies and successful start-ups in biotech, technology, and travel across Asia and USA. Have built high-performance strategy, data analytics, and business teams, resulting in major business growth, start-ups reaching profitability, and high shareholder returns (multiple highly profitable exit transactions at combined ~$2B exit valuations, plus additional strong operating businesses valued in 9 figures).

Since my first full-time job at Bain, where I was trained in developing "true north" data-driven insights and strategies for business growth, I have been excited about the power of data to build transformative businesses across many sectors and am now actively applying this approach for my entrepreneurial and investing activities.